{
  "metadata": {
    "claims_file": "test_claims.json",
    "documents": [
      "FlublokPI"
    ],
    "total_claims": 1,
    "started_at": "2025-07-29T18:08:21.901968",
    "completed_at": "2025-07-29T18:09:14.452506"
  },
  "claims": {
    "claim_000": {
      "claim_id": "claim_000",
      "claim": "Flublok Quadrivalent is approved for adults 18 years and older.",
      "started_at": "2025-07-29T18:08:21.901987",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "evidence_extractor",
              "success": true,
              "timestamp": "2025-07-29T18:08:28.035393"
            },
            {
              "agent": "evidence_verifier_v2",
              "success": true,
              "timestamp": "2025-07-29T18:08:43.114373"
            },
            {
              "agent": "completeness_checker",
              "success": true,
              "timestamp": "2025-07-29T18:08:51.722453"
            },
            {
              "agent": "evidence_verifier_v2_additional",
              "success": true,
              "timestamp": "2025-07-29T18:09:14.451781"
            },
            {
              "agent": "evidence_presenter",
              "success": true,
              "timestamp": "2025-07-29T18:09:14.452482"
            }
          ],
          "supporting_evidence": [
            {
              "quote": "Flublok is approved for use in persons 18 years of age and older. (1)",
              "explanation": "The quote 'Flublok is approved for use in persons 18 years of age and older. (1)' appears almost verbatim in the document on page 1 under the section DOSAGE FORMS AND ADMINISTRATION.. The quote explicitly states that Flublok is approved for use in persons 18 years of age and older, which directly supports the claim that Flublok Quadrivalent is approved for adults 18 years and older."
            },
            {
              "quote": "Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).",
              "explanation": "The quote is found on page 4 of the document, stating: 'Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).' The wording is slightly spaced and split but the core content matches exactly.. The quote directly indicates that Flublok Quadrivalent has been administered to adults 18 years and older, with safety data collected from these age groups, which supports the claim that Flublok Quadrivalent is approved for adults 18 years and older."
            },
            {
              "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.",
              "explanation": "The quote is found almost verbatim on page 3 of the document: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.' Minor spacing and line breaks differences exist, but the core content matches exactly.. The quote shows that Flublok Quadrivalent was studied in adults aged 18 through 49 years, indicating clinical use in this adult age group. Additionally, elsewhere in the document it is stated that Flublok is approved for use in persons 18 years of age and older. Therefore, the quote supports the claim that Flublok Quadrivalent is approved for adults 18 years and older by demonstrating clinical trial enrollment in this age group."
            },
            {
              "quote": "Flublok is approved for use in persons 18 years of age and older. (1)",
              "explanation": "The quote 'Flublok is approved for use in persons 18 years of age and older. (1)' appears almost verbatim in the document on page 1 under the DOSAGE FORMS section.. The quote explicitly states that Flublok is approved for use in persons 18 years of age and older, which directly confirms the claim that Flublok Quadrivalent is approved for adults 18 years and older."
            },
            {
              "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.",
              "explanation": "The quote is found on page 3 of the document, stating: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.' The wording is slightly different with spacing and minor formatting differences, but the core content matches exactly.. The quote directly states that Flublok Quadrivalent was studied and administered to adults aged 18 through 49 years, which supports the claim that Flublok Quadrivalent is approved for adults 18 years and older. The clinical trial enrollment of adults starting at age 18 substantiates its use and approval in this adult age group."
            },
            {
              "quote": "Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).",
              "explanation": "The quote is found near the bottom of page 3 and top of page 4 in the document. The exact text is: 'Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).' The wording is slightly spaced and split but the core content matches exactly.. The quote provides specific data that Flublok Quadrivalent has been administered to adults 18 years and older, including 998 adults aged 18-49 and 4328 adults 0 years and older (which includes adults). This supports the claim that Flublok Quadrivalent is approved for adults 18 years and older by showing clinical administration and safety data collection in this population."
            }
          ],
          "evidence_summary": {
            "total_evidence_found": 6,
            "coverage": "complete",
            "missing_aspects": []
          },
          "success": true
        }
      },
      "completed_at": "2025-07-29T18:09:14.452498"
    }
  },
  "summary": {
    "total_claim_document_pairs": 1,
    "successfully_processed": 1,
    "processing_rate": 1.0,
    "average_evidence_per_claim": 6.0,
    "coverage_distribution": {
      "complete": 1,
      "partial": 0,
      "none": 0
    }
  }
}